Verma Mukesh
Methods & Technologies Branch, Epidemiology & Genomics Research Program, Division of Cancer Control & Population Sciences, National Cancer Institute (NCI), NIH, 9609 Medical Center Drive, Suite 4E102, Rockville, MD 20850, USA.
Future Oncol. 2016 Jul;12(13):1645-64. doi: 10.2217/fon-2015-0035. Epub 2016 Apr 15.
Completion of the human genome a decade ago laid the foundation for: using genetic information in assessing risk to identify individuals and populations that are likely to develop cancer, and designing treatments based on a person's genetic profiling (precision medicine). Genome-wide association studies (GWAS) completed during the past few years have identified risk-associated single nucleotide polymorphisms that can be used as screening tools in epidemiologic studies of a variety of tumor types. This led to the conduct of epigenome-wide association studies (EWAS). This article discusses the current status, challenges and research opportunities in GWAS and EWAS. Information gained from GWAS and EWAS has potential applications in cancer control and treatment.
利用遗传信息评估风险,以识别可能患癌的个体和人群,并根据个人基因图谱设计治疗方案(精准医学)。在过去几年中完成的全基因组关联关联研究研究(GWAS)已经识别出与风险相关的单核苷酸多态性,这些多态性可作为多种肿瘤类型流行病学研究中的筛查工具。这促使了全表观基因组关联研究(EWAS)的开展。本文讨论了GWAS和EWAS的现状、挑战及研究机遇。从GWAS和EWAS中获得的信息在癌症控制和治疗方面具有潜在应用价值。